Ortho Plus
Contact Us
Acute Care

CLINICAL LABS & IMMUNODIAGNOSTICS

Cardiac Assay Menu

When seconds count, our assays provide reliable short-term and long-term risk information for patients with acute coronary syndrome. This helps your lab make a vital contribution to patient outcomes when it’s most needed.
Let’s get started
When seconds count, our assays provide reliable short-term and long-term risk information for patients with acute coronary syndrome. This helps your lab make a vital contribution to patient outcomes when it’s most needed.

Helping your lab support patients with the most urgent needs quickly

Patients presenting with chest pain and shortness of breath are time-critical emergencies that leave your lab no room for error or delay. Achieving the best patient outcomes requires the fastest intervention possible.

VITROS® Cardiac Assays offer exceptional assay performance to help provide vital information to inform treatment decisions.

Helping your lab support patients with the most urgent needs quickly

Patients presenting with chest pain and shortness of breath are time-critical emergencies that leave your lab no room for error or delay. Achieving the best patient outcomes requires the fastest intervention possible.

VITROS® Cardiac Assays offer exceptional assay performance to help provide vital information to inform treatment decisions.

For US:
VITROS® Troponin I ES Assay

Improved assay sensitivity and precision delivers reliable short-term and long-term risk information for patients with acute coronary syndrome and supports single sample testing with serum/plasma equivalence.

  • Performance competitive with a currently available 5th Generation high sensitivity Troponin assays.
  • Guideline acceptable precision. Meets ACC/ESC guidelines for acceptable imprecision in a high sensitivity assay ( 10% coefficient of variation at the 99th percentile).
  • Validated clinical performance at the 99th percentile upper reference limit of normal enables accelerated rule-in/rule-out algorithms
  • Analyzer automated sample indices help ensure that actionable results are reported.
  • False positive Troponin T results have been reported in patients with kidney disease.1 Troponin I biomarker elevations are more specific for myocardial damage than TroponinT elevations.2

REFERENCE:

1. Christenson RH et al. Comparison of 13 Commercially Available Cardiac Troponin Assays in a Multicenter North American Study. JALM 2017; March; 544-561.

2. Twerenbold R. et al., Optimal Cutoff Levels of More Sensitive Cardiac Troponin Assays for the Early Diagnosis of Myocardial Infarction in Patients With Renal Dysfunction Circulation.
2015;131:2041-2050

For ex-US:
VITROS® High-Sensitivity Troponin Assay*

  • Provides high analytical sensitivity and precision for the detection of small changes at the 99th percentile, enabling early diagnosis of acute myocardial infarction
  • Features a high negative predictive value that helps reduce emergency department crowding and requires fewer tests to diagnose
  • Meets the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) classification as a high-sensitivity troponin assay
  • Shows excellent prognostic value as an aid in the assessment of cardiac-related mortality/MI and all-cause mortality over 30 days and 12 months
  • HS Troponin assay is compliant for use with guidelines for management of acute coronary syndrome, including ESC, AHA and NICE

*VITROS High-Sensitivity Troponin Assay is not available in all countries. Please check with your local Ortho representative for availability.

 

For ex-US:
VITROS® NT-proBNP II Assay

  • NT-proBNP is more stable than BNP, which is important when samples must be transported1
  • NT-proBNP allows for better management of patients on common heart failure therapy (Entresto®) compared to BNP 2
  • Most NT-proBNP assays correlate well to each other. (Not all BNP assays correlate well with other BNP assays.)3
  • The VITROS® NT-proBNP II assay is validated with the state-of-the-art ICON cutoffs, which offer improved specificity as they account for age and renal function4-8
  • The VITROS® NT-proBNP II assay also incorporates our state-of-the-art MicroWell technology that features an analyte-specific coating designed to eliminate biotin interference

 

 

Comprehensive Care

VIPLabTech

Service & Support

Imagine going from clutter to clarity and having seamless control of your lab. Our Ortho Care® Services and Informatics gives you the freedom to focus on patient care.

See how we support you
VIPLabTech

Informatics Solutions

Is it time to change the way you see your lab? Simplify data to unburden you from the disruptions, complexities and distractions that pull your focus away from patient care. See how network insights, open connectivity and quality management can drive the change your lab needs.

Explore informatics

 

 

1Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med. 2004;42(8):942-944. doi:10.1515/CCLM.2004.153

2Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54-61. doi:10.1161/CIRCULATIONAHA.114.013748

3Collin-Chavagnac D, Dehoux M, Schellenberg F, Cauliez B, Maupas-Schwalm F, Lefevre G; Société Française de Biologie Clinique Cardiac Markers Working Group. Head-to-head comparison of 10 natriuretic peptide assays. Clin Chem Lab Med. 2015;53(11):1825-1837. doi:10.1515/cclm-2014-0592

4Kim HN, Januzzi JL Jr. Natriuretic peptide testing in heart failure. Circulation. 2011;123(18):2015-2019. doi:10.1161/CIRCULATIONAHA.110.979500

5Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006; Aug;52(8):1528-1538. doi:10.1373/clinchem.2006.069575

6Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948-954. doi:10.1016/j.amjcard.2004.12.032

7Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. Eur Heart J. 2006;27(3):330-337. doi:10.1093/eurheartj/ehi631

8Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2(6):663-670. doi:10.1016/j.jchf.2014.09.001